Adjuvant Radiation Therapy for High-Risk Cutaneous SCC of the Nose
For cutaneous squamous cell carcinoma of the nose with high-risk features after complete surgical excision, adjuvant radiation therapy should be strongly considered, as it reduces local recurrence by approximately 50% and locoregional recurrence by similar margins.
Primary Recommendation
The 2018 American Academy of Dermatology guidelines explicitly state that primary cSCC with concerning perineural invasion or otherwise at high risk for regional or distant metastasis may be considered for adjuvant radiation therapy to the local tumor site following surgical treatment 1. While the guidelines acknowledge that high-level evidence is lacking, this represents the most authoritative guidance available.
Supporting Evidence for Benefit
Recent high-quality research strongly supports adjuvant radiation in this setting:
A 2026 multicenter cohort study of 1,267 high-risk cSCC patients demonstrated that adjuvant radiation reduced local recurrence by 50% (hazard ratio 0.47), locoregional recurrence by 53% (hazard ratio 0.47), and nodal metastasis by 55% (hazard ratio 0.45) 2. The absolute benefit was substantial: 5-year local recurrence decreased from 11.9% to 5.9%.
A 2022 dual-center study of 508 high T-stage tumors showed adjuvant radiation halved the risk of both local recurrence (3.6% vs 8.7% at 5 years) and locoregional recurrence (7.5% vs 15.3%) 3.
A 2021 meta-analysis of 2,605 patients confirmed lower recurrence rates (OR 0.56), longer disease-free survival (OR 2.17), and longer overall survival (OR 2.94) with adjuvant radiation 4.
Specific High-Risk Features Warranting Adjuvant Radiation
Based on guideline and research evidence, consider adjuvant radiation when ANY of these features are present:
- Perineural invasion (especially if "concerning" or named nerve involvement) 1, 4
- Positive or close surgical margins 4
- Advanced T-stage (BWH T2b with ≥3 risk factors or T3) 2, 3
- Tumor size ≥6 cm 3
- Recurrent tumors 3
- Immunosuppression 4
- Lymphovascular invasion 2
Highest-Risk Subset
For tumors that are BWH stage T3, BWH T2 with 3+ risk factors, or have lymphovascular invasion, adjuvant radiation provides even greater absolute benefit: reducing 5-year locoregional recurrence from 36.6% to 20.0% and nodal metastasis from 21.1% to 9.6% 2.
Radiation Dosing
Multiple radiation modalities are acceptable, including superficial radiation therapy, external electron beam, or brachytherapy 1.
Typical doses range from 50-80 Gy, with a mean of 60 Gy 5. A 2025 systematic review of nasal vestibule SCC (anatomically similar to nasal SCC) found no statistically significant differences by dose or fractionation schedule, though 60 Gy appears standard 5.
Important Caveats
The nose is a cosmetically and functionally sensitive area. Radiation toxicities can include radionecrosis, fistulas, and cosmetic complications 5. This must be balanced against recurrence risk.
Smaller and thinner tumors may be more responsive to radiation 1, though this refers primarily to primary radiation rather than adjuvant use.
The guidelines acknowledge that cure rates with radiation may be lower than surgery 1, but in the adjuvant setting after complete excision, radiation targets microscopic disease.
Clinical Algorithm
- Confirm complete surgical excision with pathology review
- Identify high-risk features (perineural invasion, positive margins, T2b/T3 stage, size ≥6 cm, recurrence, immunosuppression, lymphovascular invasion)
- If ANY high-risk feature present: Refer to radiation oncology for adjuvant radiation therapy
- If MULTIPLE high-risk features or highest-risk subset: Adjuvant radiation is strongly indicated given substantial absolute benefit
- Coordinate multidisciplinary discussion between dermatology/surgical oncology and radiation oncology to optimize timing and technique
The evidence consistently demonstrates that adjuvant radiation provides meaningful reductions in recurrence and metastasis for high-risk cutaneous SCC, with the greatest benefit in patients with multiple risk factors 2, 3, 4.